<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16461">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01682109</url>
  </required_header>
  <id_info>
    <org_study_id>UMCN-AKF 11.05</org_study_id>
    <nct_id>NCT01682109</nct_id>
  </id_info>
  <brief_title>Palatability Testing of a New Paediatric Formulation of Valacyclovir - VALID 0</brief_title>
  <acronym>VALID0</acronym>
  <official_title>Palatability Testing of a New Paediatric Formulation of Valacyclovir for the Prophylaxis and Treatment of VZV and HSV Infections in Children - VALID 0</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <authority>Netherlands: Ministry of Health, Welfare and Sport</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Palatability testing of 3 different formulations of a newly developed paediatric
      valacyclovir oral solution in children 4-12 years of age and at least one of their parents.
      Children will be included, who received (val)acyclovir prophylaxis in the past, or will
      probably need it in the future i.e. children with primary immune deficiency or cancer.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    oral liquid not available
  </why_stopped>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)</study_design>
  <primary_outcome>
    <measure>Selection of oral solution with best taste</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients (children) will assess the taste of 3 different oral solutions. A questionnaire has to be completed to order the palatability of the three formulations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Taste assessment</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Children will score the taste of 3 different oral valacyclovir solutions. A 100 mm facial hedonic scale will be employed to indicate the palatability of each formulation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictability of palatability preference of the child by parents.</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine whether parents can predict the palatability preference of their child.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Varicella Zoster Virus Infection</condition>
  <condition>Herpes Simplex Virus Infection</condition>
  <arm_group>
    <arm_group_label>Raspberry</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Raspberry taste valacyclovir solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Orange</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Orange taste valacyclovir solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Plain</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Plain valacyclovir solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valacyclovir</intervention_name>
    <description>Children of 4-8 years will taste 2 ml of each solution and children of 8-12 years and the parent(s) will taste 4 ml of each solution.</description>
    <arm_group_label>Raspberry</arm_group_label>
    <arm_group_label>Orange</arm_group_label>
    <arm_group_label>Plain</arm_group_label>
    <other_name>50 mg/ml valacyclovir solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is at least 4 years of age.

          -  Subject weighs at least 15kg.

          -  Subject is capable of performing the taste assessment, according to the
             investigator's judgement.

          -  The child and parent(s) are willing to participate in the taste assessment.

          -  Signed informed consent by the legal guardian for participation of the child and if
             the parent also wants to participate: signed informed consent for their own
             participation, prior to start of the study.

        Exclusion Criteria:

          -  Documented history of sensitivity/idiosyncrasy to medicinal products or excipients.

          -  Presence of any condition that influences taste sensation (such as upper respiratory
             infection, febrile illness within 3 days before the first dose, mucositis or use of
             medication that influences taste perception, as described in the label information).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adilia Warris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 28, 2013</lastchanged_date>
  <firstreceived_date>September 5, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prophylaxis</keyword>
  <keyword>herpes zoster</keyword>
  <keyword>herpes simplex</keyword>
  <keyword>valacyclovir</keyword>
  <keyword>palatability</keyword>
  <keyword>paediatric</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Chickenpox</mesh_term>
    <mesh_term>Herpes Zoster</mesh_term>
    <mesh_term>Herpes Simplex</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Valacyclovir</mesh_term>
    <mesh_term>Acyclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
